Circulating levels of ADAM12, a stromal activation biomarker, are predictive of survival in pancreatic ductal adenocarcinoma (PDAC)

Authors :: O.R.C. Busch
Helene Damhofer
V.L. Veenstra
Frederike Dijk
Johanna W. Wilmink
R. Jiang
M.G. Besselink
C. Waasdorp
Daniel W. Pierce
M.F. Bijlsma
L.B. van Rijssen
H.W.M. van Laarhoven
J. Shiansong Li
J.P. Medema
Source :: Annals of Oncology. 28:v254-v255
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: Oncology
medicine.medical_specialty
Stromal cell
Pancreatic ductal adenocarcinoma
business.industry
Internal medicine
ADAM12
Biomarker (medicine)
Medicine
Hematology
business

Tools